We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Eye-Drug Compounder Can't Dodge Allergan Suit

Law360, New York (November 15, 2017, 9:16 PM EST) -- A California federal judge on Tuesday kept alive Allergan’s false advertising suit against a large drug compounder, saying there are sufficient allegations the compounder is manufacturing eye medicines without adhering to federal law.

In a 22-page order, U.S. District Judge David O. Carter refused to dismiss claims brought by Allergan Inc. against Imprimis Pharmaceuticals Inc. under the federal Lanham Act and California’s unfair competition law. At issue is whether Imprimis made unreliable claims regarding manufacturing and product effectiveness for drugs used by patients with cataracts or...
To view the full article, register now.




Case Information

Case Title

Allergan USA, Inc. v. Imprimis Pharmaceuticals, Inc.

Case Number



California Central

Nature of Suit

Other Statutory Actions


David O. Carter

Date Filed

September 7, 2017

Law Firms


Government Agencies

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.